BGB-26808 / BeOne Medicines - LARVOL DELTA

First-in-human, phase I study of BGB-26808 (hematopoietic progenitor kinase 1 [HPK1] inhibitor) ± tislelizumab (TIS; anti-PD-1) in advanced solid tumors (STs) (ESMO 2025) - P1 | "Conclusions Preliminary data show BGB-26808 ± TIS was generally tolerable and potential antitumor activity of BGB-26808 was shown combined with TIS. Further study of BGB-26808 + TIS ± chemotherapy is ongoing in the expansion."

First-in-human • Metastases • P1 data • Oncology • Solid Tumor

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=217 | Recruiting | Sponsor: BeiGene | N=107 ➔ 217

Enrollment change • Oncology • Solid Tumor

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=107 | Recruiting | Sponsor: BeiGene | Trial completion date: Feb 2027 ➔ Sep 2027 | Trial primary completion date: Aug 2026 ➔ Sep 2027

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

BeiGene's new HPK1-targeted cancer drug approved for clinical trials [Google translation] (bydrug.pharmcube.com) - "On September 26, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that BeiGene's Class 1 new drug BGB-26808 tablets was approved for clinical trials and is planned to be used in combination with tislelizumab for the treatment of advanced solid tumors."

New trial • Oncology • Solid Tumor